Delving into the Latest Updates on HLA-A2 restricted glioma antigen peptides vaccine(University of Pittsburgh) with Synapse

Overview

Basic Info

Drug Type

Therapeutic vaccine

Synonyms

BB 13624, BB-13624, BB13624

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

NeoplasmsNervous System DiseasesOther Diseases

Active Indication

Low grade gliomaBrain Stem GliomaHigh grade glioma+ [4]

Inactive Indication-

Originator Organization

University of Pittsburgh

Active Organization

University of Pittsburgh

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

The study will assess the immunogenicity, safety and preliminary clinical efficacy of the glioma associated antigen (GAA)/tetanus toxoid (TT) peptide vaccine and poly-ICLC in HLA-A2+ children with unresectable low-grade gliomas that have received at least two chemotherapy/biologic regimens. Radiation therapy counts as one biologic regimen, but patients may not have received radiation to the index lesion within 1 year of enrollment.

Start Date01 Jan 2015

Sponsor / Collaborator

University of Pittsburgh

[+1]

NCT01130077

/ CompletedPhase 1IIT

A Pilot Study to Evaluate the Effects of Vaccinations with HLA-A2-Restricted Glioma Antigen-Peptides with Poly-ICLC for Children with Newly Diagnosed Malignant Brain Stem Gliomas, Non-Brainstem High-Grade Gliomas, Recurrent Low-Grade Gliomas or Recurrent High Grade Gliomas

The overall objective of this pilot study is to collect immunological and safety data following administration of vaccinations with HLA-A2. This data will be used to decide whether a larger study of clinical efficacy is warranted.

Start Date01 Feb 2009

Sponsor / Collaborator

University of Pittsburgh

100 Clinical Results associated with HLA-A2 restricted glioma antigen peptides vaccine(University of Pittsburgh)

Login to view more data

100 Translational Medicine associated with HLA-A2 restricted glioma antigen peptides vaccine(University of Pittsburgh)

Login to view more data

100 Patents (Medical) associated with HLA-A2 restricted glioma antigen peptides vaccine(University of Pittsburgh)

Login to view more data

100 Deals associated with HLA-A2 restricted glioma antigen peptides vaccine(University of Pittsburgh)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Low grade glioma	Phase 2	United States	University of Pittsburgh	01 Jan 2015
Brain Stem Glioma	Phase 1	United States	University of Pittsburgh	01 Feb 2009
High grade glioma	Phase 1	United States	University of Pittsburgh	01 Feb 2009
Malignant glioma of brain	Phase 1	United States	University of Pittsburgh	01 Feb 2009
Recurrent Low Grade Astrocytoma	Phase 1	United States	University of Pittsburgh	01 Feb 2009
Recurrent Malignant Glioma	Phase 1	United States	University of Pittsburgh	01 Feb 2009
Recurrent WHO Grade II Glioma	Phase 1	United States	University of Pittsburgh	01 Feb 2009